BNTX - Glancy Prongay & Murray LLP Reminds Investors of Looming Deadline in the Class Action Lawsuit Against BioNTech SE (BNTX) | Benzinga
LOS ANGELES, Feb. 05, 2024 (GLOBE NEWSWIRE) -- Glancy Prongay & Murray LLP ("GPM") reminds investors of the upcoming March 12, 2024 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who purchased or otherwise acquired BioNTech SE ("BioNTech" or the "Company") (NASDAQ:BNTX) securities between March 30, 2022 and October 13, 2023, inclusive (the "Class Period").
If you suffered a loss on your BioNTech investments or would like to inquire about potentially pursuing claims to recover your loss under the federal securities laws, you can submit your contact information at www.glancylaw.com/cases/BioNTech-SE/. You can also contact Charles H. Linehan, of GPM at 310-201-9150, Toll-Free at 888-773-9224, or via email at shareholders@glancylaw.com to learn more about your rights.
On August 8, 2022, BioNTech released its second quarter 2022 financial results, missing consensus estimates, which the Company attributed to the "dynamic" development of the pandemic, which the Company claimed caused a "re-phasing of orders" and led to fluctuations in quarterly revenues. On this news, BioNTech's stock price fell $13.81, or 7.5%, to close at $169.30 per share on August 8, 2022, thereby injuring investors.
Then, on March 27, 2023, BioNTech released its fourth quarter and full year 2022 financial results, forecasting approximately €5 billion in COVID-19 vaccine revenues for 2023, ...
BNTX)>Full story available on Benzinga.com